ImmunityBio, Inc. (IBRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 40M 80M 120M FY13: 600K FY14: 641K FY15: 236K FY16: 44K FY17: 45K FY18: 47K FY19: 2.2M FY20: 605K FY21: 934K FY22: 240K FY23: 622K FY24: 14.7M FY25: 113.3M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 40M 80M 120M FY22: 240K FY23: 622K FY24: 14.7M FY25: 112.5M FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY14: -5.6M FY15: -238.9M FY16: -124.5M FY17: -99.1M FY18: -98.4M FY19: -156.3M FY20: -220.9M FY21: -330.3M FY22: -351.3M FY23: -362.2M FY24: -344.2M FY25: -256M FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-600M -400M -200M 0 200M 400M 600M FY13: -2M FY14: -6.2M FY15: -236.9M FY16: -120.8M FY17: -96.4M FY18: -96.2M FY19: -157.8M FY20: -221.9M FY21: -346.8M FY22: -416.6M FY23: -583.2M FY24: -413.6M FY25: -351.4M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 300K 600K 900K FY22: 0 FY23: 0 FY24: 0 FY25: 753K FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-450M -300M -150M 0 150M 300M 450M FY13: -668K FY14: -5.4M FY15: -25.3M FY16: -38.6M FY17: -48.8M FY18: -63.4M FY19: -152.1M FY20: -171.7M FY21: -274.4M FY22: -337.5M FY23: -366.8M FY24: -391.2M FY25: -304.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-450M -300M -150M 0 150M 300M 450M FY13: -671K FY14: -5.7M FY15: -27.5M FY16: -45.2M FY17: -83.6M FY18: -76.5M FY19: -156.4M FY20: -173.4M FY21: -308M FY22: -415.7M FY23: -397.3M FY24: -398.1M FY25: -308.8M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 350M 700M 1.1B FY19: 366.3M FY20: 377.1M FY21: 389.2M FY22: 399.9M FY23: 508.6M FY24: 700.4M FY25: 919.9M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '14: -0.77 Q1 '15: -0.93 Q2 '15: -2.73 Q3 '15: -3.21 Q4 '15: -3.45 Q1 '16: -3.29 Q2 '16: -1.71 Q3 '16: -1.51 Q4 '16: -1.47 Q1 '17: -1.39 Q2 '17: -1.27 Q3 '17: -1.18 Q4 '17: -1.20 Q1 '18: -1.25 Q2 '18: -1.31 Q3 '18: -1.31 Q4 '18: -1.22 Q1 '19: -1.09 Q2 '19: -0.91 Q3 '19: -0.77 Q4 '19: -0.71 Q1 '20: -0.59 Q2 '20: -0.56 Q3 '20: -0.57 Q4 '20: -0.59 Q1 '21: -0.70 Q2 '21: -0.79 Q3 '21: -0.84 Q4 '21: -0.89 Q1 '22: -0.94 Q2 '22: -0.95 Q3 '22: -1.01 Q4 '22: -1.05 Q1 '23: -1.06 Q2 '23: -1.14 Q3 '23: -1.05 Q4 '23: -1.16 Q1 '24: -1.09 Q2 '24: -0.97 Q3 '24: -0.92 Q4 '24: -0.63 Q1 '25: -0.58 Q2 '25: -0.48 Q3 '25: -0.41 Q4 '25: -0.38 Q1 '26: -0.85 Q2 '26: -0.97 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.